Vaxcyte said its 31-strain VAX-31 vaccine met all main goals in a late-stage trial, with immune responses comparable to or better than competing vaccines; shares jumped 26% premarket.
1. Trial results and plans
Vaxcyte said VAX-31 was as safe and well tolerated as current vaccines. The company expects results from two more late-stage trials in the first half of 2027 and plans to apply for FDA approval in the first half of 2028.
PCVX•
